Key Highlights
- The oral semaglutide pill from Novo Nordisk achieved its primary endpoint in a phase 3 study with pediatric type 2 diabetes patients
- Participants experienced a 0.83 percentage point greater reduction in HbA1c levels compared to placebo during the 26-week study period
- 132 participants between ages 10 and 17 were enrolled in the clinical study
- This marks the first time an oral GLP-1 medication has been tested in pediatric and adolescent populations
- The company intends to seek regulatory clearance in the United States and European Union during H2 2026
Novo Nordisk announced Thursday that its oral formulation of semaglutide successfully demonstrated blood sugar reduction in pediatric and adolescent patients diagnosed with type 2 diabetes, based on findings from a phase 3 clinical study.
The study enrolled 132 participants ranging from 10 to 17 years old and tracked outcomes over a 26-week treatment period. Those receiving the active medication experienced HbA1c reductions 0.83 percentage points greater than participants who received placebo.
Novo Nordisk characterized the findings as statistically significant and confirmed the study achieved its primary objective.
This clinical trial represents the inaugural evaluation of an oral GLP-1 medication in younger patients. To date, regulatory agencies have not approved any oral GLP-1 therapy for pediatric or adolescent use.
The medication currently markets to adults as Rybelsus and in pill form as Ozempic. The Ozempic oral formulation is anticipated to launch in U.S. markets during Q2 2026.
Type 2 diabetes historically affected primarily adult populations, but this demographic pattern has shifted dramatically. Current CDC statistics indicate approximately 364,000 American children and adolescents under age 20 have received a diabetes diagnosis.
Therapeutic Gaps in Pediatric Diabetes Care
Clinicians treating younger diabetes patients face significant limitations in available therapeutic approaches. Metformin represents the typical initial intervention, yet it proves inadequate for glycemic management in approximately 50% of adolescent cases.
Insulin therapy serves as another primary alternative, though it presents complications including hypoglycemic events and unwanted weight increases. An oral medication with favorable tolerability would address an important unmet medical need.
Martin Holst Lange, serving as Novo Nordisk’s chief scientific officer, noted the incidence of type 2 diabetes among youth has increased dramatically over the last twenty years.
“Oral semaglutide is an effective treatment option for children and adolescents with Type 2 diabetes who require glycaemic control beyond that provided by the current standard of care,” Lange said.
2026 Regulatory Submissions Targeted
The Danish pharmaceutical company announced intentions to pursue label expansion for both Rybelsus and the Ozempic pill formulation to encompass pediatric and adolescent indications, with submissions planned for the second half of 2026 in American and European markets.
Approval would establish semaglutide as the inaugural oral GLP-1 treatment authorized for younger patients.
The trial’s safety data aligned with outcomes observed in previous semaglutide studies conducted with adult subjects.
Gaining regulatory clearance would expand Novo’s semaglutide portfolio into an untapped patient segment, potentially providing the Copenhagen-based pharmaceutical manufacturer with competitive advantages over Eli Lilly (LLY) in diabetes and obesity therapeutics.
Novo Nordisk anticipates completing regulatory submissions in both jurisdictions before year-end.
